Holen Sie sich die Stockscreener-App
2.92
3.31%
-0.10
Handel nachbörslich:
2.94
0.02
+0.68%
Schlusskurs vom Vortag:
$3.02
Offen:
$3.03
24-Stunden-Volumen:
1.83M
Relative Volume:
0.58
Marktkapitalisierung:
$527.40M
Einnahmen:
$4.03M
Nettoeinkommen (Verlust:
$-198.37M
KGV:
-2.3267
EPS:
-1.255
Netto-Cashflow:
$-158.74M
1W Leistung:
-1.02%
1M Leistung:
-20.87%
6M Leistung:
-23.36%
1J Leistung:
-21.93%
1-Tages-Spanne:
$2.91
$3.04
1-Wochen-Bereich:
$2.865
$3.18
52-Wochen-Spanne:
$2.67
$6.94
Prime Medicine Inc Stock (PRME) Company Profile
Firmenname
Prime Medicine Inc
Sektor
Branche
Telefon
617-465-0013
Adresse
60 FIRST ST., CAMBRIDGE
Compare PRME vs VRTX, REGN, ARGX, RVMD, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PRME
Prime Medicine Inc
|
2.92 | 543.66M | 4.03M | -198.37M | -158.74M | -1.255 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Prime Medicine Inc Stock (PRME) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-12 | Eingeleitet | Oppenheimer | Outperform |
| 2025-05-27 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-05-20 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-05-20 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-12-10 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-05-20 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-05-16 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-04-22 | Eingeleitet | Chardan Capital Markets | Buy |
| 2024-04-08 | Eingeleitet | TD Cowen | Buy |
| 2024-04-03 | Eingeleitet | Wedbush | Outperform |
| 2024-01-16 | Herabstufung | Stifel | Buy → Hold |
| 2023-12-08 | Eingeleitet | Citigroup | Neutral |
| 2023-10-09 | Eingeleitet | BMO Capital Markets | Outperform |
| 2023-07-31 | Eingeleitet | Guggenheim | Buy |
| 2023-04-18 | Eingeleitet | Stifel | Buy |
| 2022-11-14 | Eingeleitet | Goldman | Neutral |
| 2022-11-14 | Eingeleitet | JP Morgan | Overweight |
| 2022-11-14 | Eingeleitet | Jefferies | Buy |
| 2022-11-14 | Eingeleitet | Morgan Stanley | Equal-Weight |
Alle ansehen
Prime Medicine Inc Aktie (PRME) Neueste Nachrichten
Prime Medicine Inc (PRME) Cash Flow - TradingKey
Prime Medicine Inc (PRME) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Prime Medicine Inc (PRME) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Prime Medicine Inc (PRME) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Prime Medicine Market Sentiment - Benzinga España
Prime Medicine Inc (PRME) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
PRME|Prime Medicine Inc|Price:3.015|Chg%:+0.065 - TradingKey
Analysts Offer Insights on Healthcare Companies: Atricure (ATRC), Prime Medicine, Inc. (PRME) and Community Health (CYH) - The Globe and Mail
Prime Medicine, Inc. (PRME) Stock Price, News, Quote & History - Yahoo! Finance Canada
Price to earnings forward of Prime Medicine, Inc. – NASDAQ:PRME - TradingView
First Trust Heitman Glbl Prm Rl Estt ETF (PRME) stock price, news, quote and history - Yahoo Finance UK
Prime Medicine Buy Rating Reiterated as Pipeline Advances; $6 Price Target Maintained - TipRanks
PRME|Prime Medicine Inc|Price:3.040|Chg%:+0.030 - TradingKey
Prime Medicine receives FDA clearance for Wilson disease therapy - Investing.com
Prime Medicine Announces U.S. FDA Clearance Of Investigational New Drug Application For Pm577a In H1069q-Mutated Wilson Disease - TradingView
Prime Medicine, Inc. (PRME) stock price, news, quote and history - Yahoo Finance Singapore
Prime Medicine receives FDA clearance for Wilson disease therapy By Investing.com - Investing.com Canada
Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM577a in H1069Q-mutated Wilson Disease - The Manila Times
Prime Medicine expects first-in-human Wilson trial in second half of 2026 - Stock Titan
Tracking Cathie Wood: Backing Prime Medicine and SpaceX, Sells Off AtaiBeckley, Shopify - Moomoo
PRME Surges 15% After Winning Arbitration Against Beam — Clears Path To Human Trials For Its Gene-Editing Drug - Stocktwits
Svetlana Ni Makhni Net Worth (2026) - GuruFocus
Prime Medicine secures favorable arbitration ruling in Beam Therapeutics case - MSN
Tracking Cathie Wood: Loading Up on X-Energy and Prime Medicine, Slashing AtaiBeckley - Moomoo
Prime Medicine (PRME) Reaches Positive Resolution to Arbitration with Beam Therapeutics - Yahoo Finance
Sumitomo Mitsui Trust Group Inc. Has $10.23 Million Stock Position in Prime Medicine, Inc. $PRME - MarketBeat
Prime Medicine Inc. (PRME) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Prime Medicine (NASDAQ:PRME) Shares Down 6.5%Should You Sell? - MarketBeat
Prime Medicine Stock Dips As Traders Weigh Heavy Losses - timothysykes.com
Enterprise value to EBITDA forward of Prime Medicine, Inc. – NASDAQ:PRME - TradingView
Prime Medicine gains after winning arbitration with Beam Therapeutics - MSN
PRME Stock Slides As Traders Weigh Heavy Losses And Cash Runway - StocksToTrade
Prime Medicine Down Nearly 14%, on Pace for Largest Percent Decrease Since May 2025 -- Data Talk - Moomoo
H.C. Wainwright reiterates Prime Medicine stock rating at buy By Investing.com - Investing.com Canada
H.C. Wainwright Maintains Prime Medicine(PRME.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Prime Editing Clears IP Fight, Sets Q3 Filing for First Liver-Targeted AATD Drug - Tech Times
Analysts Offer Insights on Healthcare Companies: Resmed (RMD) and Prime Medicine, Inc. (PRME) - The Globe and Mail
Prime Medicine wins arbitration to advance gene editing program, shares jump over 15%. - Pluang
Prime Medicine Beats Beam Therapeutics In Patent DisputeBut Both Are Investable (PRME) - Seeking Alpha
Morgan Stanley Maintains Prime Medicine(PRME.US) With Hold Rating - Moomoo
Prime Medicine stock surges after winning arbitration with Beam - Investing.com
Prime Medicine, Inc. (NASDAQ:PRME) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Prime Medicine Jumps 15% as Arbitration Win Clears Path for AATD Gene-Editing Human Trials - finance.biggo.com
TD Cowen reiterates Buy on Prime Medicine stock after arbitration win By Investing.com - Investing.com South Africa
Prime Medicine Receives Favorable Ruling in Beam Therapeutics License Arbitration; Shares Rise - marketscreener.com
TD Cowen reiterates Buy on Prime Medicine stock after arbitration win - Investing.com Nigeria
Prime Medicine Secures Favorable Arbitration Ruling in Beam Therapeutics Case - Benzinga
Prime Medicine wins binding arbitration against Beam Therapeutics - grafa.com
Prime Medicine Shares Rise on Positive Arbitration Ruling in Beam Dispute - Moomoo
LifeSci Capital Maintains Prime Medicine(PRME.US) With Buy Rating, Maintains Target Price $6 - Moomoo
Prime Medicine stock surges after winning arbitration with Beam By Investing.com - Investing.com Canada
Finanzdaten der Prime Medicine Inc-Aktie (PRME)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.44%
0.02%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):